newsfilter
← Latest News
PR Newswire·

Biotech's Monday Split: Two Trial Wins, One Trial Miss and an FDA Rejection

  • The S&P 500 fell 1.92% to 7,416.59 & the Nasdaq Composite dropped 2.49% to 24,509.76 on Monday, Nov. 16, 2026.
  • Research and Markets projects the global bladder cancer drugs market will grow from USD 6.89 billion in 2026 to USD 11.84 billion by 2032 at a 9.41% compound annual growth rate.
  • CG Oncology's Phase 3 PIVOT-006 trial met its primary endpoint for adjuvant intravesical cretostimogene in non-muscle invasive bladder cancer, reducing recurrence risk by 68%.
  • CG Oncology plans to submit a biologics license application in Q2 2027 & will present topline results at the Society of Urologic Oncology Annual Meeting on Dec. 2, 2026.
  • Lexeo Therapeutics reported positive interim Phase I/II data for gene therapy LX2020, showing 80% mean reduction in non-sustained ventricular tachycardia & 44% reduction in premature ventricular contractions.
  • The FDA indicated openness to using non-sustained ventricular tachycardia as a primary surrogate endpoint for Lexeo's potential accelerated approval of LX2020.
  • Summit Therapeutics shares fell 16.5% after the FDA issued a complete response letter for ivonescimab in lung cancer, citing insufficient evidence of overall survival improvement.
  • Aclaris Therapeutics reported its Phase 2 ADMIRATION trial failed to meet primary or secondary endpoints for bosakitug in atopic dermatitis, despite robust target engagement.
  • Aclaris initiated a Phase 2b ALPHA trial for modzatinib in patients with moderate-to-severe lichen planus.
Company
Biotech Today
Keywords
Biotech Today